{"id":"commercial-hepatitis-b-vaccine","safety":{"commonSideEffects":[{"rate":"10–30","effect":"Injection site pain, redness, or swelling"},{"rate":"5–15","effect":"Fatigue"},{"rate":"5–15","effect":"Headache"},{"rate":"5–10","effect":"Myalgia"},{"rate":"1–5","effect":"Low-grade fever"}]},"_chembl":{"chemblId":"CHEMBL2109163","moleculeType":"Vaccine component"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"The vaccine contains hepatitis B surface antigen (HBsAg), typically produced via recombinant DNA technology, which triggers both humoral (antibody) and cell-mediated immune responses. This immune priming enables the body to recognize and neutralize hepatitis B virus upon exposure, preventing infection and chronic disease development.","oneSentence":"A hepatitis B vaccine that stimulates the immune system to produce antibodies and cellular immunity against hepatitis B virus surface antigen, providing protection against HBV infection.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:06:48.001Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prevention of hepatitis B virus infection in unvaccinated or non-immune populations"},{"name":"Post-exposure prophylaxis in hepatitis B-exposed individuals"}]},"trialDetails":[{"nctId":"NCT03038802","phase":"PHASE1, PHASE2","title":"A Randomised Controlled Phase 1 Study of Vaccine Therapy for Control or Cure of Chronic Hepatitis B Virus Infection","status":"NOT_YET_RECRUITING","sponsor":"Vaxine Pty Ltd","startDate":"2026-03-01","conditions":"Chronic Hepatitis b","enrollment":40},{"nctId":"NCT04620226","phase":"PHASE4","title":"UHN Inpatient Hepatitis C & B Screening","status":"UNKNOWN","sponsor":"Jordan Feld","startDate":"2024-02-01","conditions":"Hepatitis C, Hepatitis B","enrollment":2920},{"nctId":"NCT01119625","phase":"PHASE3","title":"Immunological Persistence After Priming With GSK1024850A Vaccine and Safety& Immunogenicity After Booster Dose","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2010-07-12","conditions":"Infections, Streptococcal","enrollment":238},{"nctId":"NCT00808444","phase":"PHASE3","title":"Primary Vaccination Study With a Pneumococcal Conjugate Vaccine in Healthy Children 6-12wks of Age","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2009-01-05","conditions":"Infections, Streptococcal","enrollment":466},{"nctId":"NCT03405597","phase":"PHASE3","title":"HBsAb Response After HBV Vaccination in Chronic Hepatitis B Patients Who Have Lost HBsAg","status":"UNKNOWN","sponsor":"Mahidol University","startDate":"2017-03-30","conditions":"Chronic Hepatitis B, HBsAg, Hepatitis B Vaccine","enrollment":97},{"nctId":"NCT01667432","phase":"","title":"An Observational Study of Peginterferon Alfa-2a (PEGASYS®) in Patients With HBeAg Positive or HBeAg Negative Chronic Hepatitis B","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2011-07-08","conditions":"Hepatitis B, Chronic","enrollment":141},{"nctId":"NCT00805675","phase":"PHASE3","title":"Effects of Telbivudine and Tenofovir Disoproxil Fumarate Treatment on the Hepatitis B Virus DNA Kinetics in CHB","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2008-11","conditions":"Hepatitis B Virus","enrollment":83},{"nctId":"NCT00329251","phase":"PHASE4","title":"Study of the Influence of Vaccination in HIV Viral Load and Immunologic Responses Against HIV","status":"COMPLETED","sponsor":"Hospital Clinic of Barcelona","startDate":"2003-04","conditions":"HIV","enrollment":26}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":11,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Engerix B"],"phase":"phase_3","status":"active","brandName":"Commercial Hepatitis B vaccine","genericName":"Commercial Hepatitis B vaccine","companyName":"Vaxine Pty Ltd","companyId":"vaxine-pty-ltd","modality":"Biologic","firstApprovalDate":"","aiSummary":"A hepatitis B vaccine that stimulates the immune system to produce antibodies and cellular immunity against hepatitis B virus surface antigen, providing protection against HBV infection. Used for Prevention of hepatitis B virus infection in unvaccinated or non-immune populations, Post-exposure prophylaxis in hepatitis B-exposed individuals.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":2,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}